Keywords: prasugrel, lowers, hf, risk, high-risk, patients, taking
Prasugrel lowers HF risk in high-risk patients
Article | 09 March 2009
Patients taking Daiichi Sankyo and Eli Lilly's prasugrel achieved a significant reduction in relative risk of cardiovascular death, non-fatal heart ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
